Ignite Creation Date:
2024-05-06 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 2:31 PM
Study NCT ID:
NCT05356195
Status:
RECRUITING
Last Update Posted:
2024-06-13
First Post:
2022-04-07
Brief Title:
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia TDT
Sponsor:
Vertex Pharmaceuticals Incorporated
Organization:
Vertex Pharmaceuticals Incorporated
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-05-03
Start Date Type:
ACTUAL
Primary Completion Date:
2026-05
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-05
Completion Date Type:
ESTIMATED
First Submit Date:
2022-04-07
First Submit QC Date:
April 29 2022
Study First Post Date:
2022-05-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-16
Last Update Post Date:
2024-06-13
Last Update Post Date Type:
ACTUAL